| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and...
-
Nov 5, 2019- Management to host conference call today at 8:30 a.m. ET -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter...
-
Oct 31, 2019
In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq...
-
Oct 4, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2019, the independent...
-
Sep 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...
-
Sep 12, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief...
-
Aug 13, 2019- Reinhard von Roemeling, M.D., Joins Company as Senior Vice President, Clinical Development -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of Reinhard von Roemeling,...
-
Aug 6, 2019- Anti-tumor activity observed in multiple patients in initial data from the ongoing Phase 1 study of CA-4948 in non-Hodgkin Lymphoma -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter...
-
Jul 30, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second...
-
Jul 5, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2019, the independent...